Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PJPragya Jain

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis reveal venetoclax treatment improves clinical outcomes in AML through MRD negativity.

Key Points

  • MRD negativity linked to better survival in AML treated with venetoclax.
  • Pooled hazard ratios indicate improved clinical outcomes across overall survival and event free survival.
  • Analysis based on data from 6 studies investigating MRD status in AML patients receiving specific treatments.
  • Results indicate that MRD may serve as a valuable prognostic tool in venetoclax-based therapy.

Cite This Study

Pragya Jain (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b9https://doi.org/10.1182/blood-2025-1742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  2. 2Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine2025 · 1 citations
  3. 3Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025
  4. 4Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting2025 · 1 citations
  5. 5Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients2025